Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Lachmann

Showing results (131-140 of 287) with videos related to

Pageof 29
Sort By:
Clinical and Experimental Immunology|March 1, 1983
Further studies of the C3g component of the alpha 2D fragment of human C3H Chaplin, M C Monroe, P J Lachmann
International Archives of Allergy and Applied Immunology|January 1, 1973
Production of MIF and mitogenic factor in vivoZ Trnka, J B Hay, P J Lachmann
European Journal of Immunology|September 1, 1993
Construction, expression and functional analysis of a glycolipid-linked form of CR1P M Clissold, H J Ebling, P J Lachmann
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1985
Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3bG D Ross, J A Cain, P J Lachmann
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1989
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3M C Poznansky, P M Clissold, P J Lachmann
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1979
Activation of complement by Schistosoma mansoni schistosomula: killing of parasites by the alternative pathway and requirement of IgG for classical pathway activationF Santoro, P J Lachmann, A Capron, et al.
Immunology|February 1, 1992
The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugateA M Montgomery, M G Wing, P J Lachmann
International Archives of Allergy and Applied Immunology|January 1, 1980
The coagglutination phenomenon of Bordet and Gengou involves a reaction between antibody-aggregated fourth component of complement and a receptor on guniea pig red cellsR R Coombs, A B Wilson, P J Lachmann
The Biochemical Journal|May 15, 1988
Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation productsT C Farries, P J Lachmann, R A Harrison
Biological Trace Element Research|July 1, 1989
Inhibition by metals of X-ray and ultraviolet-induced DNA repair in human cellsR D Snyder, G F Davis, P J Lachmann
Pageof 29

Showing results (131-140 of 287) with videos related to

Sort By:
Pageof 29
Clinical and Experimental Immunology|March 1, 1983
Further studies of the C3g component of the alpha 2D fragment of human C3H Chaplin, M C Monroe, P J Lachmann
International Archives of Allergy and Applied Immunology|January 1, 1973
Production of MIF and mitogenic factor in vivoZ Trnka, J B Hay, P J Lachmann
European Journal of Immunology|September 1, 1993
Construction, expression and functional analysis of a glycolipid-linked form of CR1P M Clissold, H J Ebling, P J Lachmann
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1985
Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3bG D Ross, J A Cain, P J Lachmann
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1989
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3M C Poznansky, P M Clissold, P J Lachmann
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1979
Activation of complement by Schistosoma mansoni schistosomula: killing of parasites by the alternative pathway and requirement of IgG for classical pathway activationF Santoro, P J Lachmann, A Capron, et al.
Immunology|February 1, 1992
The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugateA M Montgomery, M G Wing, P J Lachmann
International Archives of Allergy and Applied Immunology|January 1, 1980
The coagglutination phenomenon of Bordet and Gengou involves a reaction between antibody-aggregated fourth component of complement and a receptor on guniea pig red cellsR R Coombs, A B Wilson, P J Lachmann
The Biochemical Journal|May 15, 1988
Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation productsT C Farries, P J Lachmann, R A Harrison
Biological Trace Element Research|July 1, 1989
Inhibition by metals of X-ray and ultraviolet-induced DNA repair in human cellsR D Snyder, G F Davis, P J Lachmann
Pageof 29